Combination therapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old with a type of stomach or gastroesophageal junction cancer that is locally advanced or has spread and cannot be removed by surgery.
- You must not have received any prior systemic treatment (like chemo or targeted pills) for this advanced cancer, but you may have had chemo or other therapy before the cancer spread if it finished at least 6 months ago.
- Your tumor must have a PD-L1 score below 1, meaning a certain protein level is low.
- You need to have at least one measurable tumor that can be assessed by scans, and you should be able to perform daily activities (ECOG 0 or 1).
- You must not have HER2-positive cancer, which is a specific marker that can be tested.
- You must not have had other cancers in the past 5 years (with a few exceptions like certain skin or cervical cancers), and you must not have active brain metastases, uncontrolled high blood pressure, recent bleeding, or blood clots.
- You must not have received certain immunotherapy drugs (anti-PD-1, anti-PD-L1, or anti-CTLA-4) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which blocks blood vessel growth to tumors), and chemotherapy for people with a specific type of stomach cancer that is MSI-H/dMMR (meaning it has many mutations and may respond better to immunotherapy). The goal is to shrink the cancer and potentially make it removable by surgery.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (albumin-bound paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.